Wells Fargo Turns Bullish on Alector, Citing Overlooked Brain Delivery Technology
Wells Fargo initiates Alector with an Overweight rating and $7 price target, citing its brain carrier platform and Alzheimer’s drug AL-137.
Wells Fargo initiates Alector with an Overweight rating and $7 price target, citing its brain carrier platform and Alzheimer’s drug AL-137.
Oppenheimer says Capricor’s Q3 update shows strong support for deramiocel in Duchenne. FDA decision expected around Nov 22; stock could hit $50.
Analyst Ryan Deschner lifted Liquidia’s rating and price target to $77, citing robust PAH demand, rising shipments, and resolved litigation with United Therapeutics.
RBC Capital downgrades Perspective Therapeutics to Sector Perform and cuts its price target to $4 after VMT-α-NET Phase 1/2a results.
Analysts see attractive risk/reward in Camp4’s SYNGAP1 program, Benitec’s gene therapy, Immunic’s MS trials, Pharvaris and Microbot’s robotic system.
Analyst sees approvable assets and places stock on Positive Catalyst Watch.